Skip to Main Content

Skip Nav Destination

ARTICLES| June 15, 1998

MLL and CALM Are Fused to AF10 in Morphologically Distinct Subsets of Acute Leukemia With Translocation t(10;11): Both Rearrangements Are Associated With a Poor Prognosis

M.H. Dreyling,

M.H. Dreyling

¹From the Department of Hematology/Oncology, University of Göttingen, Göttingen, Germany; the Institute of Medical Biology, University of Vienna, Vienna, Austria; the Institute of Human Genetics, University of Kiel, Kiel, Germany; the Robert-Rössle-Clinic, Department of Hematology/Oncology and Tumor Immunology, Humboldt-University of Berlin, Berlin, Germany; the Department of Medicine, University Hospital of Kiel, Kiel, Germany; the Department of Hematology/Oncology, University of Münster, Münster, Germany; and the Institute of Human Genetics, University of Göttingen, Göttingen, Germany.

Search for other works by this author on:

PubMed

Google Scholar

K. Schrader,

K. Schrader

¹From the Department of Hematology/Oncology, University of Göttingen, Göttingen, Germany; the Institute of Medical Biology, University of Vienna, Vienna, Austria; the Institute of Human Genetics, University of Kiel, Kiel, Germany; the Robert-Rössle-Clinic, Department of Hematology/Oncology and Tumor Immunology, Humboldt-University of Berlin, Berlin, Germany; the Department of Medicine, University Hospital of Kiel, Kiel, Germany; the Department of Hematology/Oncology, University of Münster, Münster, Germany; and the Institute of Human Genetics, University of Göttingen, Göttingen, Germany.

Search for other works by this author on:

PubMed

Google Scholar

C. Fonatsch,

C. Fonatsch

¹From the Department of Hematology/Oncology, University of Göttingen, Göttingen, Germany; the Institute of Medical Biology, University of Vienna, Vienna, Austria; the Institute of Human Genetics, University of Kiel, Kiel, Germany; the Robert-Rössle-Clinic, Department of Hematology/Oncology and Tumor Immunology, Humboldt-University of Berlin, Berlin, Germany; the Department of Medicine, University Hospital of Kiel, Kiel, Germany; the Department of Hematology/Oncology, University of Münster, Münster, Germany; and the Institute of Human Genetics, University of Göttingen, Göttingen, Germany.

Search for other works by this author on:

PubMed

Google Scholar

B. Schlegelberger,

B. Schlegelberger

¹From the Department of Hematology/Oncology, University of Göttingen, Göttingen, Germany; the Institute of Medical Biology, University of Vienna, Vienna, Austria; the Institute of Human Genetics, University of Kiel, Kiel, Germany; the Robert-Rössle-Clinic, Department of Hematology/Oncology and Tumor Immunology, Humboldt-University of Berlin, Berlin, Germany; the Department of Medicine, University Hospital of Kiel, Kiel, Germany; the Department of Hematology/Oncology, University of Münster, Münster, Germany; and the Institute of Human Genetics, University of Göttingen, Göttingen, Germany.

Search for other works by this author on:

PubMed

Google Scholar

D. Haase,

D. Haase

¹From the Department of Hematology/Oncology, University of Göttingen, Göttingen, Germany; the Institute of Medical Biology, University of Vienna, Vienna, Austria; the Institute of Human Genetics, University of Kiel, Kiel, Germany; the Robert-Rössle-Clinic, Department of Hematology/Oncology and Tumor Immunology, Humboldt-University of Berlin, Berlin, Germany; the Department of Medicine, University Hospital of Kiel, Kiel, Germany; the Department of Hematology/Oncology, University of Münster, Münster, Germany; and the Institute of Human Genetics, University of Göttingen, Göttingen, Germany.

Search for other works by this author on:

PubMed

Google Scholar

C. Schoch,

C. Schoch

¹From the Department of Hematology/Oncology, University of Göttingen, Göttingen, Germany; the Institute of Medical Biology, University of Vienna, Vienna, Austria; the Institute of Human Genetics, University of Kiel, Kiel, Germany; the Robert-Rössle-Clinic, Department of Hematology/Oncology and Tumor Immunology, Humboldt-University of Berlin, Berlin, Germany; the Department of Medicine, University Hospital of Kiel, Kiel, Germany; the Department of Hematology/Oncology, University of Münster, Münster, Germany; and the Institute of Human Genetics, University of Göttingen, Göttingen, Germany.

Search for other works by this author on:

PubMed

Google Scholar

W.-D. Ludwig,

W.-D. Ludwig

¹From the Department of Hematology/Oncology, University of Göttingen, Göttingen, Germany; the Institute of Medical Biology, University of Vienna, Vienna, Austria; the Institute of Human Genetics, University of Kiel, Kiel, Germany; the Robert-Rössle-Clinic, Department of Hematology/Oncology and Tumor Immunology, Humboldt-University of Berlin, Berlin, Germany; the Department of Medicine, University Hospital of Kiel, Kiel, Germany; the Department of Hematology/Oncology, University of Münster, Münster, Germany; and the Institute of Human Genetics, University of Göttingen, Göttingen, Germany.

Search for other works by this author on:

PubMed

Google Scholar

H. Löffler,

H. Löffler

¹From the Department of Hematology/Oncology, University of Göttingen, Göttingen, Germany; the Institute of Medical Biology, University of Vienna, Vienna, Austria; the Institute of Human Genetics, University of Kiel, Kiel, Germany; the Robert-Rössle-Clinic, Department of Hematology/Oncology and Tumor Immunology, Humboldt-University of Berlin, Berlin, Germany; the Department of Medicine, University Hospital of Kiel, Kiel, Germany; the Department of Hematology/Oncology, University of Münster, Münster, Germany; and the Institute of Human Genetics, University of Göttingen, Göttingen, Germany.

Search for other works by this author on:

PubMed

Google Scholar

T. Büchner,

T. Büchner

¹From the Department of Hematology/Oncology, University of Göttingen, Göttingen, Germany; the Institute of Medical Biology, University of Vienna, Vienna, Austria; the Institute of Human Genetics, University of Kiel, Kiel, Germany; the Robert-Rössle-Clinic, Department of Hematology/Oncology and Tumor Immunology, Humboldt-University of Berlin, Berlin, Germany; the Department of Medicine, University Hospital of Kiel, Kiel, Germany; the Department of Hematology/Oncology, University of Münster, Münster, Germany; and the Institute of Human Genetics, University of Göttingen, Göttingen, Germany.

Search for other works by this author on:

PubMed

Google Scholar

B. Wörmann,

B. Wörmann

¹From the Department of Hematology/Oncology, University of Göttingen, Göttingen, Germany; the Institute of Medical Biology, University of Vienna, Vienna, Austria; the Institute of Human Genetics, University of Kiel, Kiel, Germany; the Robert-Rössle-Clinic, Department of Hematology/Oncology and Tumor Immunology, Humboldt-University of Berlin, Berlin, Germany; the Department of Medicine, University Hospital of Kiel, Kiel, Germany; the Department of Hematology/Oncology, University of Münster, Münster, Germany; and the Institute of Human Genetics, University of Göttingen, Göttingen, Germany.

Search for other works by this author on:

PubMed

Google Scholar

W. Hiddemann,

W. Hiddemann

¹From the Department of Hematology/Oncology, University of Göttingen, Göttingen, Germany; the Institute of Medical Biology, University of Vienna, Vienna, Austria; the Institute of Human Genetics, University of Kiel, Kiel, Germany; the Robert-Rössle-Clinic, Department of Hematology/Oncology and Tumor Immunology, Humboldt-University of Berlin, Berlin, Germany; the Department of Medicine, University Hospital of Kiel, Kiel, Germany; the Department of Hematology/Oncology, University of Münster, Münster, Germany; and the Institute of Human Genetics, University of Göttingen, Göttingen, Germany.

Search for other works by this author on:

PubMed

Google Scholar

S.K. Bohlander

S.K. Bohlander

¹From the Department of Hematology/Oncology, University of Göttingen, Göttingen, Germany; the Institute of Medical Biology, University of Vienna, Vienna, Austria; the Institute of Human Genetics, University of Kiel, Kiel, Germany; the Robert-Rössle-Clinic, Department of Hematology/Oncology and Tumor Immunology, Humboldt-University of Berlin, Berlin, Germany; the Department of Medicine, University Hospital of Kiel, Kiel, Germany; the Department of Hematology/Oncology, University of Münster, Münster, Germany; and the Institute of Human Genetics, University of Göttingen, Göttingen, Germany.

Search for other works by this author on:

PubMed

Google Scholar

Blood (1998) 91 (12): 4662–4667.

https://doi.org/10.1182/blood.V91.12.4662

Abstract

The translocation t(10;11)(p13;q14) has been observed in acute lymphoblastic leukemia (ALL) as well as acute myeloid leukemia (AML). A recent study showed a MLL/AF10 fusion in all cases of AML with t(10;11) and various breakpoints on chromosome 11 ranging from q13 to q23. We recently cloned CALM (Clathrin Assembly Lymphoid Myeloid leukemia gene), the fusion partner of AF10 at 11q14 in the monocytic cell line U937. To further define the role of these genes in acute leukemias, 10 cases (9 AML and 1 ALL) with cytogenetically proven t(10;11)(p12-14;q13-21) and well-characterized morphology, immunophenotype, and clinical course were analyzed. Interphase fluorescence in situ hybridization (FISH) was performed with 2 YACs flanking the CALM region, a YAC contig of the MLLregion, and a YAC spanning the AF10 breakpoint. Rearrangement of at least one of these genes was detected in all cases with balanced t(10;11). In 4 cases, including 3 AML with immature morphology (1 AML-M0 and 2 AML-M1) and 1 ALL, the signals of the CALM YACS were separated in interphase cells, indicating a translocation breakpoint within the CALM region. MLL was rearranged in 3 AML with myelomonocytic differentiation (2 AML-M2 and 1 AML-M5), including 1 secondary AML. In all 3 cases, a characteristic immunophenotype was identified (CD4⁺, CD13⁻, CD33⁺, CD65s⁺).AF-10 was involved in 5 of 6 evaluable cases, including 1 case without detectable CALM or MLL rearrangement. In 2 complex translocations, none of the three genes was rearranged. All cases had a remarkably poor prognosis, with a mean survival of 9.6 ± 6.6 months. For the 7 AML cases that were uniformly treated according to the AMLCG86/92 protocols, disease-free and overall survival was significantly worse than for the overall study group (P = .03 and P = .01, respectively). We conclude that the t(10;11)(p13;q14) indicates CALM and MLL rearrangements in morphologically distinct subsets of acute leukemia and may be associated with a poor prognosis.

MALIGNANT TRANSFORMATION is a multistep process that involves the sequential alteration of genes regulating cell growth and/or differentiation. Many of the genes involved in leukemogenesis have been identified by the molecular analysis of nonrandom chromosome abnormalities.1

The rare, but recurring translocation t(10;11)(p13;q14) has been observed in acute lymphoblastic leukemia (ALL) as well as acute myeloid leukemia (AML).2-5 A recent study showed a MLL/AF10fusion in all cases of AML with t(10;11) and various breakpoints on chromosome 11q, including 6 cases with rearrangement of chromosomal band 11q13.6,MLL (also calledALL1, Htrx1, and HRX) is involved in translocations with up to 40 different translocation partner genes in AML as well as acute lymphoid leukemia, including the t(10;11)(p13;q23) in AML.7-12 In this translocation, the fusion partner genesAF-10 and MLL are often found to be involved in complex rearrangements (inversions/insertions), because they are transcribed in opposite direction relative to the telomere/centromere orientation.6 These complex rearrangements may be interpreted as t(10;11) (p13;q14-21).

The molecular characterization of the t(10;11)(p13;q14) in the monocytic cell line U937 identified a different breakpoint on chromosome 11, involving the previously unknown geneCALM.13,14,CALM has a very high homology to the murine clathrin assembly protein ap-3.15Interestingly, both translocations t(10;11) have the same fusion partner gene on chromosome 10, the putative transcription factorAF10.11,14 16

To further define the involvement of the three genes AF10,CALM, and MLL in acute leukemias, we analyzed 10 cases (9 AML and 1 ALL) with cytogenetically proven t(10;11)(p12-14;q13-21) and well-characterized morphology, immunophenotype, and clinical course. Only cytogenetic material stored in fixative for several years was available, which was not suitable for an analysis at the RNA level. An interphase fluorescence in situ hybridization (FISH) approach was chosen.17 Nonchimeric YACs from the genomic region of the three genes were used. A translocation was assumed when one of the YAC signals was split resulting in three hybridization signals in a diploid interphase nucleus.

MATERIALS AND METHODS

Patient samples.

This study was designed and performed according to the updated declaration of Helsinki. Patient material was collected from 725 cases that entered the studies of the German AML Cooperative Group 86 and 92 and that were subjected to cytogenetic analysis.18 Based on the cytogenetic data and the availability of material, 8 cases with t(10;11)(p12-14;q13-21) were identified (Table 1). In addition, 1 adult ALL (no. 10) and 1 infant AML (no. 6) with t(10;11) were included in this series. All cases were morphologically classified according to the French-American-British (FAB) criteria and were reviewed by an independent reference hematologist (H.L.).19Immunophenotyping was performed according to the consensus protocol for flow cytometric immunophenotyping of hematopoietic malignancies.20,21 Clinical data were obtained from the AMLCG study center or directly from the patients' physicians (patients no. 6 and 10). Patients no. 3 and 7 had been previously treated for malignant T-cell lymphoma and were in complete remission. All AML patients received a uniform chemotherapy according to the AMLCG86/92 protocols comprising double induction, followed by intensive consolidation and 3 years of monthly maintenance therapy.18Patient no. 6 (pediatric patient) and patient no. 8 (initially misclassified as ALL) were treated differently (Table 1).

Mononuclear cells of patient samples were grown in short-term culture or processed directly, harvested using standard cytogenetic techniques, and stored in Carnoy's solution until final analysis, as previously published.22

FISH probes.

YAC-derived FISH probes were generated either by a sequence-independent amplification technique or nick translation (MLLYACs).23 24

For AF10, a YAC (807b3, 1,050 kb) from the Centre d'Etude Polymorphisme Humain (CEPH) library had been previously identified that spans the breakpoint region on 10p and reliably detects the breakpoint in U937.14

For MLL, we used a pool of two YACs (785c6 and 856b9) that span the MLL gene and approximately 1.0 mega-bp of distally flanking sequences, because 11q23 translocations are often associated with interstitial deletions.17,25 26

For CALM, the Mega-YAC Library from CEPH was screened with the previously reported CALM primers NG.T45 and NG.B362.14 In addition, 5 flanking YACs of the region were identified using the Whitehead web pages (www.genome.wi.mit.edu).27 28 A total of 9 YACs were evaluated by FISH for chimerism (hybridization with normal peripheral blood cells) and were mapped relative to theCALM breakpoint (hybridization with U937). Based on the intensity of hybridization signal, 2 YACs (proximal 785c1, 1,390 kb, and distal 914D9, 1,190 kb) were chosen for interphase analysis.

Hybridization.

Dual-color FISH was performed with the two YAC-derived probes of theCALM region as well as the AF10 YAC or the MLLprobe and the corresponding centromeric probe (CEP10 and CEP11 Spectrum Orange; Vysis, Downers Grove, IL) to exclude numerical chromosomal aberrations (Fig 1).

Fig. 1.

Fig. 1. (A through C) Interphase FISH of patient no. 1 (AML withAF10 and CALM rearrangement, Table 1). Three AF10 signals (green), indicating a split of one YAC signal, and two centromere 10 signals (red) are detectable in (A). In (B), the proximal (green) and the distal CALM YAC (red) are separated, indicating a breakpoint within this genomic region. Two MLL signals (green) and two centromere 11 signals (red) suggest no rearrangement of the MLL region in (C). (D through F) Interphase FISH of patient no. 8 (AML with AF10 and MLL rearrangement). Three AF-10 signals (green), indicating a split of one YAC signal, and two centromere 10 signals (red) are detectable in (D). In (E), the proximal (green) and the distal CALM YAC (red) are colocalized, excluding a rearrangement of this genomic region. In (F), the detection of three MLL signals (green), but only two centromere 11 signals (red) indicate a split of one MLL probe (C).

View large Download PPT

(A through C) Interphase FISH of patient no. 1 (AML withAF10 and CALM rearrangement, Table 1). Three AF10 signals (green), indicating a split of one YAC signal, and two centromere 10 signals (red) are detectable in (A). In (B), the proximal (green) and the distal CALM YAC (red) are separated, indicating a breakpoint within this genomic region. Two MLL signals (green) and two centromere 11 signals (red) suggest no rearrangement of the MLL region in (C). (D through F) Interphase FISH of patient no. 8 (AML with AF10 and MLL rearrangement). Three AF-10 signals (green), indicating a split of one YAC signal, and two centromere 10 signals (red) are detectable in (D). In (E), the proximal (green) and the distal CALM YAC (red) are colocalized, excluding a rearrangement of this genomic region. In (F), the detection of three MLL signals (green), but only two centromere 11 signals (red) indicate a split of one MLL probe (C).

FISH was performed as previously described.29 Briefly, the hybridization solution contained approximately 0.1 μg of each probe, 1 μg human Cot1-DNA, 0.6 μg human placental DNA, and 1 μg salmon sperm DNA/slide in a 10 μL volume. The probes were either directly labeled with Cy-3-dUTP (Vysis) or biotinylated and detected with fluorescein isothiocyanate (FITC)-conjugated avidin and amplified with antiavidin-FITC (16-Bio-dUTP [Boehringer Mannheim, Germany]; FITC-avidin and FITC anti-avidin [Vector, Burlingame, CA]). The slides were counterstained with 4′,6′-diamidino-2-phenylindole dihydrochloride (DAPI) and were analyzed using a fluorescence microscope (Zeiss, Jena, Germany). For each case, at least 100 single, intact interphase cells were analyzed.

For Fig 1, separate gray scale images of DAPI-stained cells and fluorescence signals were captured using a charge-coupled device camera (Xillix, Richmond, British Columbia, Canada) and were pseudocolored and merged using Adobe Photoshop software (Adobe Systems, Mountain View, CA).

Statistical analysis.

Survival data were analyzed using the χ² test using PC Statistik software (Topsoft, Hannover, Germany).

RESULTS

Patients' characteristics.

Our study group included 1 adult T-ALL (no. 10, Table 1), 1 infant AML (no. 6), and 8 adult AML. The morphology of the myeloid leukemias were classified as immature (FAB M0) in 1 case (no. 8) and as leukemia with minimal maturation (FAB M1) in 3 cases (no. 5, 7, and 9). Significant maturation at or beyond the promyelocyte stage (FAB M2) was diagnosed in 2 cases (no. 2 and 3) and monocytic differentiation (FAB M5) in 3 cases (no. 1, 4, and 6).

Leukocyte counts at presentation were high, but varied significantly within the study group (mean, 23,900/μL; range, 200 to 60,800/μL). All patients with t(10;11) were rather young (36.7 ± 19.9 years old). There was no gender bias (5 male and 5 female).

FISH/cytogenetics.

Rearrangements of AF10 and/or either CALM orMLL were detected in all cases with balanced t(10;11).MLL rearrangements were detected in 3 of 8 cases (no. 1, 2, and 3; Table 1), including the only cytogenetically identified inversion 11.

CALM was rearranged in another 4 patients (no. 7 through 10) with balanced translocation t(10;11).

All 5 cases of 7 with MLL or CALM rearrangements, which were evaluable, had a rearrangement of AF10. In addition, in 1 case (no. 6) with a balanced translocation t(10;11), the AF10probe was split, indicating a breakpoint within this region, but noMLL or CALM rearrangements were detected.

No rearrangements were detected in the 2 patients with complex rearrangements (no. 4 and 5). However, for case no. 4, cell material was only sufficient for hybridization with the CALMprobes.

Morphology and immunophenotype.

All cases with MLL rearrangement showed a myeloid maturation at or beyond the promyelocyte stage or a monocytic morphology according to the FAB classification (M2 or M5), including 1 secondary AML after treatment for high malignant T-cell lymphoma.19

In contrast, cases with CALM rearrangement showed a rather immature phenotype (M0 or M1). In fact, case no. 8 was initially misdiagnosed as ALL and treated accordingly.

A CALM rearrangement was detected in the only ALL in this series. The morphological diagnosis was confirmed by the typical immunophenotype with expression of various T-cell antigens and coexpression of CD10, but absence of a myeloid marker (CD11c) or B-cell antigens.

A complete immunophenotype was available in only 1 of 3 AML withCALM rearrangement (no. 7). In agreement with the undifferentiated morphology of this case, leukemic blasts expressed antigens often associated with immature morphologic subtypes (ie, CD7 and CD34). Of the panmyeloid antigens tested, only CD13 was weakly expressed. Additionally, however, strong positivity of myeloperoxidase was found.

All 3 cases with MLL rearrangement were positive for the panmyeloid antigens CD33 and CD65s but lacked CD13 and CD15 and coexpressed CD4. Expression of markers associated with immaturity varied. In addition, 1 case (no. 1) showed coexpression of CD7 and CD10.

Clinical course.

In agreement with previous reports, hyperleukocytosis was detected in all cases with MLL rearrangements (mean, 35,000/μL; range, 13,800 to 60,800/μL).30-33 Leukocyte counts were also high in cases with CALM rearrangements (mean, 27,400/μL; range, 1,300 to 60,800/μL). However, the number of cases is too small for statistical evaluation.

The overall survival of the total group was remarkably poor (9.6 ± 6.6 months), although, initially, 5 of 8 evaluable patients reached a complete remission. There was no significant difference between patients with MLL or CALM rearrangements. For the 7 patients who were treated according to the AMLCG86/92 protocol, disease-free survival and overall survival were 5 ± 4.9 months and 11 ± 7.2 months, respectively. The survival data of these patients were significantly worse than for the overall study group. After 14 months, none of the t(10;11) patients but 40% of the overall group were still disease-free (P = .03, χ²), and after 19 months, none of the t(10;11) patients but 49% of the overall group were still alive (P = .01, χ²; Fig 2).18

Fig. 2.

Fig. 2. Overall survival in AML with t(10;11). Kaplan-Meier plots of the overall survival of patients with AML with t(10;11)(p13;q14) (n = 7; solid line) and the total study group with identical treatment (n = 725; dotted line).18

View large Download PPT

Overall survival in AML with t(10;11). Kaplan-Meier plots of the overall survival of patients with AML with t(10;11)(p13;q14) (n = 7; solid line) and the total study group with identical treatment (n = 725; dotted line).18

DISCUSSION

The translocation t(10;11)(p13;q14) is a recurring chromosomal abnormality that has been observed in acute lymphoblastic as well as AML.2-5 On the molecular level, two types of t(10;11)(p12-p14;q13-q21) have been characterized so far. One type results in a MLL/AF10 fusion, the other causes aCALM/AF10 fusion.11,14 We performed this study to define the relevance of MLL and CALM rearrangements in acute leukemia with t(10;11)(p13;q13-21). Both types of rearrangements were detected with similar frequency in cases with balanced translocation t(10;11). CALM was rearranged in AML as well as in ALL. Interestingly, the AML cases with CALM rearrangement had a rather immature morphology, and 1 case was initially misdiagnosed as ALL. This may have been also the case for some of the initially reported ALL cases with t(10;11) when immunophenotyping was not yet routinely performed.3 However, our series included a well-characterized lymphoblastic leukemia as well as myeloid leukemias, suggesting that CALM may play a critical role in the early progenitor/stem cell before either myeloid or lymphoid differentiation takes place. CALM has a very high homology to ap-3, a murine clathrin assembly protein.15 So far, CALM is the only protein interacting with clathrin that has been found to be involved in malignant transformation. A transactivation domain that was recently identified in CALM could be critical for the transformation potential of CALM/AF10.34 However, further studies are necessary to define the precise mechanism by which the CALM/AF10 fusion contributes to malignant transformation.

In contrast to the rather undifferentiated morphology of myeloid leukemias with CALM rearrangement, cases with MLLrearrangement showed a monocytic morphology or a myeloid maturation beyond the promyelocyte stage. Accordingly, all previously reported leukemias with t(10;11) and rearrangement of MLL either detected by FISH or by other molecular techniques, were AML-M4 or M5/M5a.6,35,36 Similarly, MLL rearrangements in general are strongly correlated with monocytic or myelomonocytic phenotypes.30,36 In contrast, Poirel et al37detected MLL rearrangements in 20% of AML-M1. However, these translocations did not involve chromosome 10. In fact, althoughMLL rearrangements are detected in AML as well as ALL, different translocation partner genes are usually involved.36 For example, t(4;11) and t(11;19)(q23;p13.3) are detected in ALL, whereas t(6;11), t(9;11), and t(11;19)(q23;p13.1) are common translocations in various subtypes of AML.36Therefore, the results of Poirel et al37 that included t(6;11),t(9;11), and an uncharacterized t(11;19) might not be applicable to leukemias with t(10;11).

In accordance with a previously published series of AML withMLL rearrangements, in our series, all 3 cases with MLLrearrangement were CD4⁺, CD13⁻, CD33⁺, CD65s⁺.20 The latter three markers are panmyeloid markers that are rather broadly expressed.21 Therefore, this immunophenotype does not represent an aberrant expression of different lineage- or maturity-specific markers as detected in the majority of leukemias.38 Hence, we do not consider this immunophenotype as leukemia-specific for MLL translocation, although the only completely characterized AML with CALM rearrangement had a clearly distinct immunophenotype (CD4⁻, CD13⁺, CD33⁻, CD65s⁻).

AF10 is the first fusion partner of MLL, which is fused to another gene in a different translocation, emphasizing its important role in malignant transformation. It is thought that AF10functions as a transcription factor and that the zinc finger might constitute a DNA binding domain.12,16 Interestingly, 1 case with a balanced translocation t(10;11) (no. 6) showed a breakpoint within the AF10 region, but did not have a CALM orMLL rearrangement. Translocations of 11q23 are often associated with distal interstitial deletions that would make it difficult to detect the translocation by FISH. However, our MLL probe, which encompasses approximately 1 mega-bp of 3′ flanking sequences, was able to detect these kinds of translocations in previous studies.17 35 Alternatively, another partner gene on chromosome 11 may be involved.

So far, MLL rearrangements have been shown to be a negative prognostic factor, especially in childhood ALL.31-33 For AML, data are sparse and contradictory. In a series of pediatric AML, patients with t(9;11)(p22;q23) had a better outcome, whereas Lo Coco et al39 identified MLL rearrangements as a negative prognostic factor in ALL and AML.39,40 In infant AML, 11q23/MLL abnormalities had no effect on survival.31

In our study, all cases with t(10;11) had a remarkably poor prognosis. This holds up for the subpopulation of 7 AMLCG86/92 patients whose event-free and overall survival was significantly worse than the survival data of the overall study group.18 Therefore, our results suggest that cytogenetic/molecular analysis may be used to identify this subgroup with poor prognosis.

In summary, we were able to identify a MLL or a CALMrearrangement, each in approximately half of the leukemias with a t(10;11)(p13,q13-21). Moreover, MLL or CALMrearrangements were found in leukemias with different morphology.MLL translocations were identified in leukemias with monocytic morphology or maturation beyond the promyeloid stage, whereasCALM rearrangements were detectable in immature leukemias as well as ALL. Further studies are necessary to characterize the biological characteristics of these molecular alterations.

Recently, Kobayashi et al41 reported 4 cases of acute leukemia with CALM rearrangements that were studied by FISH. However, the cases were not classified according to the FAB criteria.

ACKNOWLEDGMENT

The authors thank H. Döhner for generously providing the MLL YACs and C. Sauerland for assistance in statistical analysis.

Address reprint requests to M.H. Dreyling, MD, Department of Hematology/Oncology, University of Göttingen, Robert Koch-Street 40, D-37075 Göttingen, Germany.

The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" is accordance with 18 U.S.C. section 1734 solely to indicate this fact.

REFERENCES

1

Rowley

JD

Molecular cytogenetics: Rosetta stone for understanding cancer—Ninth G. H. A. Clowes memorial award lecture.

Cancer Res

50

1990

3816

2

Berger

R

Flandrian

G

Bernheim

A

Le Coniat

M

Vecchione

D

Pacot

A

Derre

J

Daniel

M-T

Valensi

F

Sigaux

F

Ochoa-Nogguera

ME

Cytogenetic studies on 519 consecutive de novo acute nonlymphocytic leukemias.

Cancer Genet Cytogenet

29

1987

9

3

Berger

R

Le Coniat

M

Derre

J

Vechione

D

Chen

SJ

Chromosomal rearrangement on chromosome 11q14-q21 in T-cell acute lymphoblastic leukemia.

Leukemia

3

1989

560

4

Heim

S

Bekassy

A

Garwicz

S

Heldrup

J

Kristoffersson

U

Mandahal

N

Wiebe

T

Mitelmann

F

Bone marrow karyotypes in 94 children with acute leukemia.

Eur J Hematol

44

1989

227

5

Sait

SNJ

Dal Cin

P

Sandberg

AA

Recurrent involvement of 11q13 in acute nonlymphocytic leukemia.

Cancer Cytogenet Cytogenet

26

1987

351

6

Beverloo

HB

Le Coniat

M

Wijsman

J

Lillington

DM

Bernard

O

de Klein

A

van Wering

E

Welborn

J

Young

BD

Hagemeijer

A

Berger

R

Breakpoint heterogeneity in t(10;11) translocation in AML-M4/M5 resulting in fusion of AF10 and MLL is resolved by fluorescent in situ hybridization analysis.

Cancer Res

55

1995

4220

7

Ziemin-van der Pool

S

McCabe

NR

Gill

HJ

Espinosa

R

Patel

Y

Harden

A

Rubinelli

P

Smith

SD

Le Beau

MM

Rowley

JD

Diaz

MO

Identification of a gene, MLL, that spans the breakpoint in 11q23 translocations associated with human leukemias.

Proc Natl Acad Sci USA

88

1991

10735

8

Cimino

G

Moir

DT

Canaani

O

Williams

K

Christ

WM

Katzav

S

Cannizzaro

L

Lange

B

Nowell

PC

Croce

CM

Canaani

E

Cloning of ALL-1, the locus involved in leukemias with the t(4;11)(q21;q23), t(9;11)(p22;q23), and t(11;19)(q23;p13) chromosome translocations.

Cancer Res

51

1991

6712

9

Djabali

M

Selleri

L

Parry

P

Bower

M

Young

BD

Evans

GA

A trithorax-like gene is interrupted by chromosome 11q23 translocations in acute leukemias.

Nat Genet

2

1992

113

10

Tkachuk

DC

Kohler

S

Cleary

ML

Involvement of a homolog of Drosophila trithorax by 11q23 chromosomal translocations in acute leukemias.

Cell

71

1992

691

11

Chaplin

T

Ayton

P

Bernard

OA

Saha

V

Della Valle

V

Hillion

J

Gregorini

A

Lillington

D

Berger

R

Young

BD

A novel class of zinc finger/leucine zipper genes identified from the molecular cloning of the t(10;11) translocation in acute leukemia.

Blood

85

1995

1435

12

Chaplin

T

Bernard

O

Beverloo

HB

Saha

V

Hagemeijer

A

Berger

R

Young

BD

The t(10;11) translocation in acute myeloid leukemia (M5) consistently fuses the leucine zipper motif of AF10 onto the HRX gene.

Blood

86

1995

2073

13

Sundström

C

Nilsson

K

Establishment and characterization of a human histiocytic lymphoma cell line (U-937).

Int J Cancer

17

1976

565

14

Dreyling

MH

Martinez-Climent

JA

Zheng

M

Mao

J

Rowley

JD

Bohlander

SK

The t(10;11)(p13;q14) in the U937 cell line results in the fusion of the AF10 gene and CALM, a new member of the AP-3 clathrin assembly protein family.

Proc Natl Acad Sci USA

93

1996

4804

15

Morris

SA

Schroder

S

Plessmann

U

Weber

K

Ungewickell

E

Clathrin assembly protein AP180: Primary structure, domain organization and identification of a clathrin binding site.

EMBO J

12

1993

667

16

Saha

V

Chaplin

T

Gregorini

A

Ayton

P

Young

BD

The leukemia-associated-protein (LAP) domain, a cysteine-rich motif, is present in a wide range of proteins including MLL, AF10, and MLLT proteins.

Proc Natl Acad Sci USA

92

1995

9735

17

Fischer

K

Scholl

C

Salat

J

Fröhling

S

Schlenk

R

Bentz

M

Stilgenbauer

S

Lichter

P

Döhner

H

Design and validation of DNA probe sets for a comprehensive interphase cytogenetic analysis of acute myeloid leukemia.

Blood

88

1996

3962

18

Büchner

T

Intensified therapy of acute myeloid leukemia: Results of the German AML cooperative group

Büchner

T

Hiddemann

W

Wörmann

B

Haematology and Blood Tranfusion, vol. 38: Acute Leukemias VI.

1997

769

Springer

Berlin, Germany

19

Bennett

JM

Catovsky

C

Daniel

MT

Flandrin

G

Galton

DAG

Gralnick

HR

Sultan

C

Proposals for the classification of the acute leukemias.

Br J Haematol

33

1976

451

20

Creutzig

U

Harbott

J

Sperling

C

Ritter

J

Zimmermann

M

Löffler

H

Riehm

H

Schellong

G

Ludwig

W-D

Clinical significance of surface antigen expression in children with acute myeloid leukemia: Results of study AML-BFM-87.

Blood

86

1995

3097

21

Rothe

G

Schmitz

G

Adorf

D

Barlage

S

Gramatzki

M

Hanenberg

H

Höffkes

HG

Janossy

G

Knüchel

R

Ludwig

WD

Nebe

T

Nerl

C

Orfao

A

Serke

S

Sonnen

R

Tichelli

A

Wörmann

B

Consensus protocol for the flow cytometric immunophenotyping of hematopoietic malignancies.

Leukemia

10

1996

877

22

Stollmann

B

Fonatsch

C

Havers

W

Persistent Epstein-Barr virus infection associated with monosomy 7 or chromosome 3 abnormality in childhood myeloproliferative disorders.

Br J Haematol

60

1985

183

23

Bohlander

SK

Espinosa

R III

Fernald

AA

Rowley

JD

Le Beau

MM

Diaz

M

Sequence-independent amplification and labeling of yeast artificial chromosomes for fluorescence in situ hybridization.

Cytogenet Cell Genet

65

1994

108

24

Rowley

JD

Diaz

MO

Espinosa

R III

Patel

YD

van Melle

E

Ziemin

S

Taillon-Miller

P

Lichter

P

Evans

GA

Kersey

JH

Ward

DC

Domer

PH

Le Beau

MM

Mapping chromosome band 11q23 in human acute leukemia with biotinylated probes: Identification of 11q23 translocation breakpoints with a yeast artificial chromosome.

Proc Natl Acad Sci USA

87

1992

9358

25

Kobayashi

H

Espinosa

RI

Thirman

MJ

Gill

HJ

Fernald

AA

Diaz

MO

Le Beau

MM

Rowley

JD

Heterogeneity of breakpoints of 11q23 rearrangements in hematologic malignancies identified by fluorescence in situ hybridization.

Blood

82

1993

547

26

Cherif

D

Bernard

O

Paulien

S

James

MR

Le Paslier

D

Berger

R

Hunting 11q23 deletions with fluorescence in situ hybridization.

Leukemia

8

1994

578

27

Hudson

T

Stein

L

Gerety

S

Ma

J

Castle

A

Silva

J

Slonim

D

Baptosa

R

Kruglya

KL

Xu

S

Hu

X

Colbert

A

Rosenberg

C

Reeve-Daly

MP

Rozen

S

Hui

L

Wu

X

Vestergaard

C

Wilson

K

Bae

J

Maitra

S

Ganiatsas

S

Evans

C

DeAngelis

M

Ingalis

K

Nahf

R

Horton

L

Oskin

M

Collymore

A

Ye

W

Kouyoumjian

V

Zernsteva

J

Tarn

J

Devine

R

Courtney

D

Renaud

M

Nguyen

H

O'Connor

T

Fizames

C

Faure

S

Gyapay

G

Dib

C

Morissette

J

Orlin

J

Birren

B

Goodman

N

Weissenbach

J

Hawkins

T

Foote

S

Page

D

Lander

E

An STS-based map of the human genome.

Science

270

1995

1945

28

Dib

C

Faure

S

Fizames

C

Samson

D

Drouot

N

Vignal

A

Millasseau

P

Marc

S

Hazan

J

Seboun

E

Lathrop

M

Gyapay

G

Morisette

J

Weissenbach

J

A comprehensive genetic map of the human genome based on 5,264 microsatellites.

Nature

380

1996

152

29

Dreyling

MH

Bohlander

SK

Le Beau

MM

Olopade

OI

Refined mapping of genomic rearrangements involving the short arm of chromosome 9 in acute lymphoblastic leukemia and other hematological malignancies.

Blood

86

1995

1931

30

Sorensen

PHB

Chien-Shing

C

Smith

FO

Arthur

DC

Domer

PH

Bernstein

ID

Korsmeyer

SJ

Hammond

GD

Kersey

JH

Molecular rearrangements of the MLL gene are present in most cases of infant acute myeloid leukemia and are strongly correlated with monocytic or myelomonocytic phenotypes.

J Clin Invest

93

1994

429

31

Pui

CH

Ribeiro

RC

Campana

D

Raimondi

SC

Hancock

ML

Behm

FG

Sandlund

JT

Rivera

GK

Evans

WE

Crist

WM

Krance

R

Prognostic factors in the acute lymphoid and myeloid leukemias of infants.

Leukemia

10

1996

952

32

Cimino

G

Rapanotti

MC

Rivolta

A

Lo Coco

F

D'Arcangelo

E

Rondelli

R

Basso

G

Barisone

E

Rosanda

C

Santostasi

T

Canaani

E

Masera

G

Mandelli

F

Biondi

A

Prognostic relevance of ALL-1 gene rearrangement in infant acute leukemias.

Leukemia

9

1995

391

33

Behm

FG

Raimondi

SC

Frestedt

JL

Liu

Q

Crist

WM

Downing

JR

Rivera

GK

Kersey

JH

Pui

CH

Rearrangement of the MLL gene confers a poor prognosis in childhood acute lymphoblastic leukemia, regardless of presenting age.

Blood

87

1996

2870

34

Bohlander

SK

Bartels

S

Identification and mapping of a transcriptional activation domain in CALM, the fusion partner of AF10 in the t(10,11)(p13;q14) found in the monocytic cell line U937.

Med Genet

9

1997

44

35

Berger

R

Le Coniat

M

Flexor

M-A

Leblanc

T

Translocation t(10;11) involving the MLL gene in acute myeloid leukemia. Importance of fluorescence in situ hybridization (FISH) analysis.

Ann Genet

39

1995

147

36

Thirman

MJ

Gill

HJ

Burnett

RC

Mbangkollo

D

McCabe

NR

Kobayashi

H

Ziemin-van der Poel

S

Kaneko

Y

Morgan

R

Sandberg

AA

Chaganti

RSK

Larson

RA

Le Beau

MM

Diaz

MO

Rowley

JD

Rearrangement of the MLL gene in acute lymphoblastic and acute myeloid leukemias with 11q23 chromosomal translocations.

N Engl J Med

329

1993

909

37

Poirel

H

Rack

K

Delabesse

E

Radford-Weiss

I

Troussard

X

Debert

C

Leboeuf

D

Bastard

C

Picard

F

Veil-Buzyn

A

Flandrin

G

Bernard

O

Macintyre

E

Incidence and characterization of MLL gene (11q23) rearrangements in acute myeloid leukemia M1 and M5.

Blood

87

1996

2496

38

Wörmann

B

Safford

M

Könemann

S

Büchner

T

Hiddemann

W

Terstappen

LWMM

Detection of aberrant antigen expression in acute myeloid leukemia by multiparameter flow cytometry.

Recent Results Cancer Res

131

1993

185

39

Lo Coco

F

Mandelli

F

Breccia

M

Annino

L

Guglielmi

C

Petti

MC

Testi

AM

Alimena

G

Croce

CM

Canaani

E

Cimino

G

Southern blot analysis of ALL-1 rearrangements at chromosome 11q23 in acute leukemia.

Cancer Res

53

1993

3800

40

Martinez-Climent

JA

Espinosa

RI

Thirman

MJ

Le Beau

MM

Rowley

JD

Abnormalities of chromosome band 11q23 and the MLL gene in pediatric myelomonocytic and monoblastic leukemias. Identification of the t(9;11) as an indicator of long survival.

J Pediatr Hematol Oncol

17

1995

277

41

Kobayashi

H

Hosoda

F

Maseki

N

Sakurai

M

Imashuku

S

Ohki

M

Kaneko

Y

Hematologic malignancies with the t(10;11)(p13;q21) have the same molecular event and a variety of morphologic or immunologic phenotypes.

Genes Chromosom Cancer

20

1997

253

Copyright © 1998 American Society of Hematology

1998

Sign in via your Institution

Supplemental data

Fig. 1.

Fig. 1. (A through C) Interphase FISH of patient no. 1 (AML withAF10 and CALM rearrangement, Table 1). Three AF10 signals (green), indicating a split of one YAC signal, and two centromere 10 signals (red) are detectable in (A). In (B), the proximal (green) and the distal CALM YAC (red) are separated, indicating a breakpoint within this genomic region. Two MLL signals (green) and two centromere 11 signals (red) suggest no rearrangement of the MLL region in (C). (D through F) Interphase FISH of patient no. 8 (AML with AF10 and MLL rearrangement). Three AF-10 signals (green), indicating a split of one YAC signal, and two centromere 10 signals (red) are detectable in (D). In (E), the proximal (green) and the distal CALM YAC (red) are colocalized, excluding a rearrangement of this genomic region. In (F), the detection of three MLL signals (green), but only two centromere 11 signals (red) indicate a split of one MLL probe (C).

View large Download PPT

(A through C) Interphase FISH of patient no. 1 (AML withAF10 and CALM rearrangement, Table 1). Three AF10 signals (green), indicating a split of one YAC signal, and two centromere 10 signals (red) are detectable in (A). In (B), the proximal (green) and the distal CALM YAC (red) are separated, indicating a breakpoint within this genomic region. Two MLL signals (green) and two centromere 11 signals (red) suggest no rearrangement of the MLL region in (C). (D through F) Interphase FISH of patient no. 8 (AML with AF10 and MLL rearrangement). Three AF-10 signals (green), indicating a split of one YAC signal, and two centromere 10 signals (red) are detectable in (D). In (E), the proximal (green) and the distal CALM YAC (red) are colocalized, excluding a rearrangement of this genomic region. In (F), the detection of three MLL signals (green), but only two centromere 11 signals (red) indicate a split of one MLL probe (C).

Fig. 2.

Fig. 2. Overall survival in AML with t(10;11). Kaplan-Meier plots of the overall survival of patients with AML with t(10;11)(p13;q14) (n = 7; solid line) and the total study group with identical treatment (n = 725; dotted line).18

View large Download PPT

Overall survival in AML with t(10;11). Kaplan-Meier plots of the overall survival of patients with AML with t(10;11)(p13;q14) (n = 7; solid line) and the total study group with identical treatment (n = 725; dotted line).18

Table 1.

Characteristics of Acute Leukemias With t(10;11)

No.	Sex/ Age (yr)	Leuko	Diagnosis	Induction Therapy	Resp	Survival (mos)		Immunophenotype				Karyotype	FISH
No.	Sex/ Age (yr)	Leuko	Diagnosis	Induction Therapy	Resp	EventFree	Overall	B-Cell	T-Cell	Myeloid	Other	Karyotype	AF10	CALM	MLL
1	M/51	60,800	AMLM5A	TAD-HAM	CR	14	15	CD19⁻	CD2⁻ CD4⁺ CD7⁺	CD13⁻ CD14⁻ CD15⁻ CD33⁺ CD65s⁺	CD10⁽⁺⁾ CD34⁻ HLA-DR⁺ TDT⁻	46,XY, t(10;11)(p13;q14)	Split	N	Split
2	F/46	130,300	AMLM2	TAD-TAD	CR	15	19	CD19⁻	CD2⁻ CD4⁺ CD7⁻	CD13⁻ CD14⁻ CD15⁻ CD33⁺ CD65s⁺	CD10⁻ CD34⁺ HLA-DR⁺ TDT⁻	48,XX, +6,+8, t(10;11)(p12-13;q14-21)	ND	N	Split
3	F/39	13,800	sec. AMLM2	TAD-HAM	ED	<1	<1	CD19⁻	CD2⁻ CD4⁺ CD7⁻	CD13⁻ CD14⁻ CD15⁻ CD33⁺ CD65s⁺	CD10⁻ CD34⁻ HLA-DR⁺ TDT⁻	45, X, −X, der(10)t(10;11)(p12-13;q13.1) inv(11)(q13.1q23.1), der(11)t(10;11)(p12-13;q13.1)	ND	N	Split
4	F/74	200	AMLM5	TAD-HAM^*	CR	2	14	CD19⁻	CD2⁻ CD4⁺ CD7⁻	CD13⁻ CD14⁻ CD15⁻ CD33⁺ CD65s⁺	CD10⁻ CD34⁺ HLA-DR⁺ TDT⁽⁺⁾	46, XX, t(10;11;17)(p13;q13;q23)	ND	N	ND
5	F/37	4,000	AMLM1	TAD-HAM	CR	8	16	CD19⁻	CD2⁺ CD4⁻ CD7⁻	CD13⁺ CD14⁻ CD15⁺ CD33⁻ CD65s⁺	CD10⁻ CD34⁺ HLA-DR⁺ TDT⁻	46, XX, der(10)t(10;11)(p12-13;q21) der(11)t(10;11;11;16) (p12-13;q21;p14-15;q13-22) del(11)(p13), del(12)(p11.2)	N	N	N
6	M/2	NA	AMLM5	AML-BFM87	NA	NA	5	CD19⁻	CD2⁻ CD4⁻ CD7⁻	CD13⁻ CD14⁻ CD15⁺ CD33⁺ CD65s⁺	CD10⁻ CD34⁻ HLA-DR⁺ TDT⁻	46, XY, t(10;11)(p12;q21)	Split	N	N
7	M/19	1,300	sec. AMLM1	TAD-HAM	ED	1	1	CD19⁻	CD2⁻ CD4⁻ CD7⁽⁺⁾	CD13⁽⁺⁾ CD14⁻ CD15⁻ CD33⁻ CD65s⁻	CD10⁻ CD34⁺ HLA-DR⁺ TDT⁻	46, XY, t(10;11)(p13;q14)	Split	Split	N
8	M/47	20,000	AMLM0	T-ALL	ED	3	3	CD19⁻	CD3⁻	CD13⁺ CD33⁺	ND	48, XY, +3,add(7)(q33-35), der(9), der(9), +der(9), t(10;11)(p13;q21), der(12)t(12;18)(p11;q11), −18, +mar	Split	Split	N
9	F/21	60,800	AMLM1	TAD-HAM	CR	7	11	ND	ND	ND	ND	47, XX, +19, t(10;11)(p13-14;q14-21)	Split	Split	N
10	M/31	NA	T-ALL	CHOEP	NA	7	11	CD22⁻	CD1⁺ CD3⁺ CD4⁺ CD5⁺	CD11c⁻	CD10⁺ HLA-DR⁻	46, XY, del(7)(q34-q35), i(9)(q10), t(10;11)(p1?4;q14), der(17)t(1;17)(p13;p11)	ND	Split	N

No.	Sex/ Age (yr)	Leuko	Diagnosis	Induction Therapy	Resp	Survival (mos)		Immunophenotype				Karyotype	FISH
No.	Sex/ Age (yr)	Leuko	Diagnosis	Induction Therapy	Resp	EventFree	Overall	B-Cell	T-Cell	Myeloid	Other	Karyotype	AF10	CALM	MLL
1	M/51	60,800	AMLM5A	TAD-HAM	CR	14	15	CD19⁻	CD2⁻ CD4⁺ CD7⁺	CD13⁻ CD14⁻ CD15⁻ CD33⁺ CD65s⁺	CD10⁽⁺⁾ CD34⁻ HLA-DR⁺ TDT⁻	46,XY, t(10;11)(p13;q14)	Split	N	Split
2	F/46	130,300	AMLM2	TAD-TAD	CR	15	19	CD19⁻	CD2⁻ CD4⁺ CD7⁻	CD13⁻ CD14⁻ CD15⁻ CD33⁺ CD65s⁺	CD10⁻ CD34⁺ HLA-DR⁺ TDT⁻	48,XX, +6,+8, t(10;11)(p12-13;q14-21)	ND	N	Split
3	F/39	13,800	sec. AMLM2	TAD-HAM	ED	<1	<1	CD19⁻	CD2⁻ CD4⁺ CD7⁻	CD13⁻ CD14⁻ CD15⁻ CD33⁺ CD65s⁺	CD10⁻ CD34⁻ HLA-DR⁺ TDT⁻	45, X, −X, der(10)t(10;11)(p12-13;q13.1) inv(11)(q13.1q23.1), der(11)t(10;11)(p12-13;q13.1)	ND	N	Split
4	F/74	200	AMLM5	TAD-HAM^*	CR	2	14	CD19⁻	CD2⁻ CD4⁺ CD7⁻	CD13⁻ CD14⁻ CD15⁻ CD33⁺ CD65s⁺	CD10⁻ CD34⁺ HLA-DR⁺ TDT⁽⁺⁾	46, XX, t(10;11;17)(p13;q13;q23)	ND	N	ND
5	F/37	4,000	AMLM1	TAD-HAM	CR	8	16	CD19⁻	CD2⁺ CD4⁻ CD7⁻	CD13⁺ CD14⁻ CD15⁺ CD33⁻ CD65s⁺	CD10⁻ CD34⁺ HLA-DR⁺ TDT⁻	46, XX, der(10)t(10;11)(p12-13;q21) der(11)t(10;11;11;16) (p12-13;q21;p14-15;q13-22) del(11)(p13), del(12)(p11.2)	N	N	N
6	M/2	NA	AMLM5	AML-BFM87	NA	NA	5	CD19⁻	CD2⁻ CD4⁻ CD7⁻	CD13⁻ CD14⁻ CD15⁺ CD33⁺ CD65s⁺	CD10⁻ CD34⁻ HLA-DR⁺ TDT⁻	46, XY, t(10;11)(p12;q21)	Split	N	N
7	M/19	1,300	sec. AMLM1	TAD-HAM	ED	1	1	CD19⁻	CD2⁻ CD4⁻ CD7⁽⁺⁾	CD13⁽⁺⁾ CD14⁻ CD15⁻ CD33⁻ CD65s⁻	CD10⁻ CD34⁺ HLA-DR⁺ TDT⁻	46, XY, t(10;11)(p13;q14)	Split	Split	N
8	M/47	20,000	AMLM0	T-ALL	ED	3	3	CD19⁻	CD3⁻	CD13⁺ CD33⁺	ND	48, XY, +3,add(7)(q33-35), der(9), der(9), +der(9), t(10;11)(p13;q21), der(12)t(12;18)(p11;q11), −18, +mar	Split	Split	N
9	F/21	60,800	AMLM1	TAD-HAM	CR	7	11	ND	ND	ND	ND	47, XX, +19, t(10;11)(p13-14;q14-21)	Split	Split	N
10	M/31	NA	T-ALL	CHOEP	NA	7	11	CD22⁻	CD1⁺ CD3⁺ CD4⁺ CD5⁺	CD11c⁻	CD10⁺ HLA-DR⁻	46, XY, del(7)(q34-q35), i(9)(q10), t(10;11)(p1?4;q14), der(17)t(1;17)(p13;p11)	ND	Split	N

Clinical, immunophenotypic, and cytogenetic characteristics and FISH results of acute leukemias (9 AML and 1 ALL) with t(10;11).

Abbreviations: Leuko, leukocytes per microliter at presentation; Resp, response; CR, complete response; ED, early death; NA, not available; (+), weakly positive; N, not split; ND, not done/evaluable (no material left for patients no. 4 and 10; poor sample quality for patients no. 2 and 3); ALL-BFM87, combined chemotherapy following the BFM87 protocol²⁰; T-ALL, intensified combined chemotherapy for adult T-cell lymphoblastic leukemia; CHOEP, combined chemotherapy (Cyclophosphamide/Adriamycin/Vincristin/Etoposide/Prednisolon).

*Reduced dose.

1

Rowley

JD

Molecular cytogenetics: Rosetta stone for understanding cancer—Ninth G. H. A. Clowes memorial award lecture.

Cancer Res

50

1990

3816

2

Berger

R

Flandrian

G

Bernheim

A

Le Coniat

M

Vecchione

D

Pacot

A

Derre

J

Daniel

M-T

Valensi

F

Sigaux

F

Ochoa-Nogguera

ME

Cytogenetic studies on 519 consecutive de novo acute nonlymphocytic leukemias.

Cancer Genet Cytogenet

29

1987

9

3

Berger

R

Le Coniat

M

Derre

J

Vechione

D

Chen

SJ

Chromosomal rearrangement on chromosome 11q14-q21 in T-cell acute lymphoblastic leukemia.

Leukemia

3

1989

560

4

Heim

S

Bekassy

A

Garwicz

S

Heldrup

J

Kristoffersson

U

Mandahal

N

Wiebe

T

Mitelmann

F

Bone marrow karyotypes in 94 children with acute leukemia.

Eur J Hematol

44

1989

227

5

Sait

SNJ

Dal Cin

P

Sandberg

AA

Recurrent involvement of 11q13 in acute nonlymphocytic leukemia.

Cancer Cytogenet Cytogenet

26

1987

351

6

Beverloo

HB

Le Coniat

M

Wijsman

J

Lillington

DM

Bernard

O

de Klein

A

van Wering

E

Welborn

J

Young

BD

Hagemeijer

A

Berger

R

Breakpoint heterogeneity in t(10;11) translocation in AML-M4/M5 resulting in fusion of AF10 and MLL is resolved by fluorescent in situ hybridization analysis.

Cancer Res

55

1995

4220

7

Ziemin-van der Pool

S

McCabe

NR

Gill

HJ

Espinosa

R

Patel

Y

Harden

A

Rubinelli

P

Smith

SD

Le Beau

MM

Rowley

JD

Diaz

MO

Identification of a gene, MLL, that spans the breakpoint in 11q23 translocations associated with human leukemias.

Proc Natl Acad Sci USA

88

1991

10735

8

Cimino

G

Moir

DT

Canaani

O

Williams

K

Christ

WM

Katzav

S

Cannizzaro

L

Lange

B

Nowell

PC

Croce

CM

Canaani

E

Cloning of ALL-1, the locus involved in leukemias with the t(4;11)(q21;q23), t(9;11)(p22;q23), and t(11;19)(q23;p13) chromosome translocations.

Cancer Res

51

1991

6712

9

Djabali

M

Selleri

L

Parry

P

Bower

M

Young

BD

Evans

GA

A trithorax-like gene is interrupted by chromosome 11q23 translocations in acute leukemias.

Nat Genet

2

1992

113

10

Tkachuk

DC

Kohler

S

Cleary

ML

Involvement of a homolog of Drosophila trithorax by 11q23 chromosomal translocations in acute leukemias.

Cell

71

1992

691

11

Chaplin

T

Ayton

P

Bernard

OA

Saha

V

Della Valle

V

Hillion

J

Gregorini

A

Lillington

D

Berger

R

Young

BD

A novel class of zinc finger/leucine zipper genes identified from the molecular cloning of the t(10;11) translocation in acute leukemia.

Blood

85

1995

1435

12

Chaplin

T

Bernard

O

Beverloo

HB

Saha

V

Hagemeijer

A

Berger

R

Young

BD

The t(10;11) translocation in acute myeloid leukemia (M5) consistently fuses the leucine zipper motif of AF10 onto the HRX gene.

Blood

86

1995

2073

13

Sundström

C

Nilsson

K

Establishment and characterization of a human histiocytic lymphoma cell line (U-937).

Int J Cancer

17

1976

565

14

Dreyling

MH

Martinez-Climent

JA

Zheng

M

Mao

J

Rowley

JD

Bohlander

SK

The t(10;11)(p13;q14) in the U937 cell line results in the fusion of the AF10 gene and CALM, a new member of the AP-3 clathrin assembly protein family.

Proc Natl Acad Sci USA

93

1996

4804

15

Morris

SA

Schroder

S

Plessmann

U

Weber

K

Ungewickell

E

Clathrin assembly protein AP180: Primary structure, domain organization and identification of a clathrin binding site.

EMBO J

12

1993

667

16

Saha

V

Chaplin

T

Gregorini

A

Ayton

P

Young

BD

The leukemia-associated-protein (LAP) domain, a cysteine-rich motif, is present in a wide range of proteins including MLL, AF10, and MLLT proteins.

Proc Natl Acad Sci USA

92

1995

9735

17

Fischer

K

Scholl

C

Salat

J

Fröhling

S

Schlenk

R

Bentz

M

Stilgenbauer

S

Lichter

P

Döhner

H

Design and validation of DNA probe sets for a comprehensive interphase cytogenetic analysis of acute myeloid leukemia.

Blood

88

1996

3962

18

Büchner

T

Intensified therapy of acute myeloid leukemia: Results of the German AML cooperative group

Büchner

T

Hiddemann

W

Wörmann

B

Haematology and Blood Tranfusion, vol. 38: Acute Leukemias VI.

1997

769

Springer

Berlin, Germany

19

Bennett

JM

Catovsky

C

Daniel

MT

Flandrin

G

Galton

DAG

Gralnick

HR

Sultan

C

Proposals for the classification of the acute leukemias.

Br J Haematol

33

1976

451

20

Creutzig

U

Harbott

J

Sperling

C

Ritter

J

Zimmermann

M

Löffler

H

Riehm

H

Schellong

G

Ludwig

W-D

Clinical significance of surface antigen expression in children with acute myeloid leukemia: Results of study AML-BFM-87.

Blood

86

1995

3097

21

Rothe

G

Schmitz

G

Adorf

D

Barlage

S

Gramatzki

M

Hanenberg

H

Höffkes

HG

Janossy

G

Knüchel

R

Ludwig

WD

Nebe

T

Nerl

C

Orfao

A

Serke

S

Sonnen

R

Tichelli

A

Wörmann

B

Consensus protocol for the flow cytometric immunophenotyping of hematopoietic malignancies.

Leukemia

10

1996

877

22

Stollmann

B

Fonatsch

C

Havers

W

Persistent Epstein-Barr virus infection associated with monosomy 7 or chromosome 3 abnormality in childhood myeloproliferative disorders.

Br J Haematol

60

1985

183

23

Bohlander

SK

Espinosa

R III

Fernald

AA

Rowley

JD

Le Beau

MM

Diaz

M

Sequence-independent amplification and labeling of yeast artificial chromosomes for fluorescence in situ hybridization.

Cytogenet Cell Genet

65

1994

108

24

Rowley

JD

Diaz

MO

Espinosa

R III

Patel

YD

van Melle

E

Ziemin

S

Taillon-Miller

P

Lichter

P

Evans

GA

Kersey

JH

Ward

DC

Domer

PH

Le Beau

MM

Mapping chromosome band 11q23 in human acute leukemia with biotinylated probes: Identification of 11q23 translocation breakpoints with a yeast artificial chromosome.

Proc Natl Acad Sci USA

87

1992

9358

25

Kobayashi

H

Espinosa

RI

Thirman

MJ

Gill

HJ

Fernald

AA

Diaz

MO

Le Beau

MM

Rowley

JD

Heterogeneity of breakpoints of 11q23 rearrangements in hematologic malignancies identified by fluorescence in situ hybridization.

Blood

82

1993

547

26

Cherif

D

Bernard

O

Paulien

S

James

MR

Le Paslier

D

Berger

R

Hunting 11q23 deletions with fluorescence in situ hybridization.

Leukemia

8

1994

578

27

Hudson

T

Stein

L

Gerety

S

Ma

J

Castle

A

Silva

J

Slonim

D

Baptosa

R

Kruglya

KL

Xu

S

Hu

X

Colbert

A

Rosenberg

C

Reeve-Daly

MP

Rozen

S

Hui

L

Wu

X

Vestergaard

C

Wilson

K

Bae

J

Maitra

S

Ganiatsas

S

Evans

C

DeAngelis

M

Ingalis

K

Nahf

R

Horton

L

Oskin

M

Collymore

A

Ye

W

Kouyoumjian

V

Zernsteva

J

Tarn

J

Devine

R

Courtney

D

Renaud

M

Nguyen

H

O'Connor

T

Fizames

C

Faure

S

Gyapay

G

Dib

C

Morissette

J

Orlin

J

Birren

B

Goodman

N

Weissenbach

J

Hawkins

T

Foote

S

Page

D

Lander

E

An STS-based map of the human genome.

Science

270

1995

1945

28

Dib

C

Faure

S

Fizames

C

Samson

D

Drouot

N

Vignal

A

Millasseau

P

Marc

S

Hazan

J

Seboun

E

Lathrop

M

Gyapay

G

Morisette

J

Weissenbach

J

A comprehensive genetic map of the human genome based on 5,264 microsatellites.

Nature

380

1996

152

29

Dreyling

MH

Bohlander

SK

Le Beau

MM

Olopade

OI

Refined mapping of genomic rearrangements involving the short arm of chromosome 9 in acute lymphoblastic leukemia and other hematological malignancies.

Blood

86

1995

1931

30

Sorensen

PHB

Chien-Shing

C

Smith

FO

Arthur

DC

Domer

PH

Bernstein

ID

Korsmeyer

SJ

Hammond

GD

Kersey

JH

Molecular rearrangements of the MLL gene are present in most cases of infant acute myeloid leukemia and are strongly correlated with monocytic or myelomonocytic phenotypes.

J Clin Invest

93

1994

429

31

Pui

CH

Ribeiro

RC

Campana

D

Raimondi

SC

Hancock

ML

Behm

FG

Sandlund

JT

Rivera

GK

Evans

WE

Crist

WM

Krance

R

Prognostic factors in the acute lymphoid and myeloid leukemias of infants.

Leukemia

10

1996

952

32

Cimino

G

Rapanotti

MC

Rivolta

A

Lo Coco

F

D'Arcangelo

E

Rondelli

R

Basso

G

Barisone

E

Rosanda

C

Santostasi

T

Canaani

E

Masera

G

Mandelli

F

Biondi

A

Prognostic relevance of ALL-1 gene rearrangement in infant acute leukemias.

Leukemia

9

1995

391

33

Behm

FG

Raimondi

SC

Frestedt

JL

Liu

Q

Crist

WM

Downing

JR

Rivera

GK

Kersey

JH

Pui

CH

Rearrangement of the MLL gene confers a poor prognosis in childhood acute lymphoblastic leukemia, regardless of presenting age.

Blood

87

1996

2870

34

Bohlander

SK

Bartels

S

Identification and mapping of a transcriptional activation domain in CALM, the fusion partner of AF10 in the t(10,11)(p13;q14) found in the monocytic cell line U937.

Med Genet

9

1997

44

35

Berger

R

Le Coniat

M

Flexor

M-A

Leblanc

T

Translocation t(10;11) involving the MLL gene in acute myeloid leukemia. Importance of fluorescence in situ hybridization (FISH) analysis.

Ann Genet

39

1995

147

36

Thirman

MJ

Gill

HJ

Burnett

RC

Mbangkollo

D

McCabe

NR

Kobayashi

H

Ziemin-van der Poel

S

Kaneko

Y

Morgan

R

Sandberg

AA

Chaganti

RSK

Larson

RA

Le Beau

MM

Diaz

MO

Rowley

JD

Rearrangement of the MLL gene in acute lymphoblastic and acute myeloid leukemias with 11q23 chromosomal translocations.

N Engl J Med

329

1993

909

37

Poirel

H

Rack

K

Delabesse

E

Radford-Weiss

I

Troussard

X

Debert

C

Leboeuf

D

Bastard

C

Picard

F

Veil-Buzyn

A

Flandrin

G

Bernard

O

Macintyre

E

Incidence and characterization of MLL gene (11q23) rearrangements in acute myeloid leukemia M1 and M5.

Blood

87

1996

2496

38

Wörmann

B

Safford

M

Könemann

S

Büchner

T

Hiddemann

W

Terstappen

LWMM

Detection of aberrant antigen expression in acute myeloid leukemia by multiparameter flow cytometry.

Recent Results Cancer Res

131

1993

185

39

Lo Coco

F

Mandelli

F

Breccia

M

Annino

L

Guglielmi

C

Petti

MC

Testi

AM

Alimena

G

Croce

CM

Canaani

E

Cimino

G

Southern blot analysis of ALL-1 rearrangements at chromosome 11q23 in acute leukemia.

Cancer Res

53

1993

3800

40

Martinez-Climent

JA

Espinosa

RI

Thirman

MJ

Le Beau

MM

Rowley

JD

Abnormalities of chromosome band 11q23 and the MLL gene in pediatric myelomonocytic and monoblastic leukemias. Identification of the t(9;11) as an indicator of long survival.

J Pediatr Hematol Oncol

17

1995

277

41

Kobayashi

H

Hosoda

F

Maseki

N

Sakurai

M

Imashuku

S

Ohki

M

Kaneko

Y

Hematologic malignancies with the t(10;11)(p13;q21) have the same molecular event and a variety of morphologic or immunologic phenotypes.

Genes Chromosom Cancer

20

1997

253